文献速递急性肾损伤

DNA结合蛋白YB-1参与中性粒细胞胞外诱捕网介导的肾损伤及跨器官效应

DNA binding protein YB-1 is a part of the neutrophil extracellular trap mediation of kidney damage and cross-organ effects.
PubMed 文献 · Kidney Int · 2023-03-22

一项观察性研究在心脏开胸手术后患者中发现,发生急性肾损伤(AKI)者血中性粒细胞数显著高于未发生AKI者,且AKI患者血清中中性粒细胞胞外诱捕网(NETs)组分dsDNA、组蛋白3和YB-1在术后24小时内升高。小鼠实验显示,预防性给予YB-1中和抗体可显著减轻双侧缺血再灌注和脂多糖模型的肾小管损伤,延迟治疗模型中也观察到损伤减轻,提示YB-1是NETs形成过程的一部分及跨器官效应的整合介质。

要点

  • 心脏开胸术后AKI患者血中性粒细胞数显著高于非AKI患者(12.9±5.4 vs 10.1±2.9 ×10⁹ cells/L)。
  • AKI患者术后24小时内血清NETs组分dsDNA、组蛋白3和YB-1升高。
  • 小鼠模型中预防性或延迟给予YB-1中和抗体均显著减轻肾小管损伤评分。

核心结论

  • 阻断细胞外YB-1可减轻缺氧和NETs形成在肾脏中诱导的效应并显著限制AKI,提示YB-1是NETs形成过程的一部分及跨器官效应的整合介质。

研究设计与样本

  • 观察性研究:比较心脏开胸术后发生AKI的13例患者与未发生AKI的25例患者的血中性粒细胞数及血清NETs组分。
  • 动物实验:在模拟心脏手术肾脏低灌注的双侧缺血再灌注(I/R)模型和全身脂多糖(LPS)给药模型中,给小鼠施用YB-1中和抗体,并设非特异性IgG对照。
  • 动物实验:在延迟治疗模型中评估YB-1拮抗对AKI的影响。

主要发现

  • AKI组血中性粒细胞数为12.9±5.4 ×10⁹ cells/L,非AKI组为10.1±2.9 ×10⁹ cells/L,AKI组显著高于非AKI组。
  • 后来发生AKI的患者在术后24小时内血清dsDNA、组蛋白3和YB-1水平升高。
  • LPS模型中预防性YB-1抗体组肾小管损伤评分为0.65±0.18,非特异性IgG对照组为0.92±0.23(损伤评分范围1-4)。
  • I/R模型中预防性YB-1抗体组肾小管损伤评分为1.86±0.44,非特异性IgG对照组为2.42±0.23。
  • 延迟治疗模型中YB-1拮抗组肾小管损伤评分为2.58±0.18,非特异性IgG对照组为3.03±0.31,YB-1拮抗改善了AKI。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Open-heart surgery is associated with high morbidity, with acute kidney injury (AKI) being one of the most commonly observed postoperative complications. Following open-heart surgery, in an observational study we found significantly higher numbers of blood neutrophils in a group of 13 patients with AKI compared to 25 patients without AKI (AKI: 12.9±5.4 ×109 cells/L; non-AKI: 10.1±2. 9 ×109 cells/L). Elevated serum levels of neutrophil extracellular trap (NETs) components, such as dsDNA, histone 3, and DNA binding protein Y-box protein (YB)-1, were found within the first 24 hours in patients who later developed AKI. We could demonstrate that NET formation and hypoxia triggered the release of YB-1, which was subsequently shown to act as a mediator of kidney tubular damage. Experimentally, in two models of AKI mimicking kidney hypoperfusion during cardiac surgery (bilateral ischemia/reperfusion (I/R) and systemic lipopolysaccharide (LPS) administration), a neutralizing YB-1 antibody was administered to mice. In both models, prophylactic YB-1 antibody administration significantly reduced the tubular damage (damage score range 1-4, the LPS model: non-specific IgG control, 0.92±0.23; anti-YB-1 0.65±0.18; and in the I/R model: non-specific IgG control 2.42±0.23; anti-YB-1 1.86±0.44). Even in a therapeutic, delayed treatment model, antagonism of YB-1 ameliorated AKI (damage score, non-specific IgG control 3.03±0.31; anti-YB-1 2.58±0.18). Thus, blocking extracellular YB-1 reduced the effects induced by hypoxia and NET formation in the kidney and significantly limited AKI, suggesting that YB-1 is part of the NET formation process and an integral mediator of cross-organ effects.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Wang J, Liu X, Gu Y, et al. DNA binding protein YB-1 is a part of the neutrophil extracellular trap mediation of kidney damage and cross-organ effects. Kidney Int. 2023. PMID: 36963487. doi:10.1016/j.kint.2023.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。